問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Endocrinology

Division of General Internal Medicine

更新時間：2023-09-19

張淳堆Chang, Chwen-Tzuei
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

  • D0054@mail.cmuh.org.tw

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張淳堆

China Medical University Hospital

Division of Endocrinology

List

16Cases

2009-02-27 - 2010-05-05

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2006-01-26 - 2011-01-26

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2007-02-01 - 2008-04-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-07-01 - 2010-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2010-03-01 - 2012-07-31

Phase III

A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once daily in patients with type 2 diabetes, cardiovascular disease and hypertension, who exhibit inadequate glycaemic control on usual care

  • Condition/Disease

    type 2 diabetes

  • Test Drug

    dapagliflozin

Participate Sites
9Sites

Terminated9Sites

2010-06-15 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-06-15 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-04-01 - 2012-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-07-31 - 2014-09-30

Phase III

An open-label, randomized, multi-center, parallel grouped clinical trial comparing the efficacy and safety of Mylan's Insulin Glargine and Lantus® for patients with type 2 diabetes.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Mylan′s Insulin Glargine

Participate Sites
7Sites

Terminated7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB